why choose us

First received: July 10, 2023

Clinical Trial: A Study to Assess Safety and Efficacy of CHO-H01 in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Non-Hodgkin Lymphoma

Study Type: INTERVENTIONAL


Official Title: A Phase I/IIa, Open-label, Multicenter Study of the Safety and Efficacy of CHO-H01 as a Single Agent to Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

Brief Summary: This is a 2-part study.Part 1/Phase 1 of the study will be conducted to determine the safety and tolerability of CHO-H01 in subjects with relapsed/refractory CD20+ non-Hodgkin's lymphoma.It will also determine maximum tolerated dose (MTD) and recommended phase II dose (RP2D).Part 2/Phase 2 will assess the anticancer activity and safety of CHO-H01 in subjects with relapsed/refractory CD20+ non-Hodgkin's lymphoma.

Read more